Sreyashi Basu

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2020

Collaborators (6)

Matthew Campbell

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Louis Maximilian Buja

Professor

The University of Texas Health Science Center at Houston

UNITED STATES

View details

Jan A. Burger

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Lynette Phillips

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Sangeeta Goswami

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Philip A Thompson

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sreyashi Basu

Research Interests

Explore related searches

Contact this professor

Articles (11)

Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial

Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy.

Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome

Investigative needle core biopsies support multimodal deep-data generation in glioblastoma

Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

Collaborators (6)

Matthew Campbell

Louis Maximilian Buja

Jan A. Burger

Lynette Phillips

Sangeeta Goswami

Philip A Thompson

Make your next move.